0
Research question

How long does reconstituted ipamorelin last?

Reconstituted ipamorelin in bacteriostatic water is typically referenced to a 28-day in-use stability window when stored refrigerated at 2-8 °C. The framework follows the standard bacteriostatic-water-plus-peptide-stability logic that applies across the catalog.

What the research literature says

Ipamorelin’s pentapeptide structure (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is engineered for protease resistance through the N-terminal aminoisobutyric acid residue and D-amino-acid substitutions at multiple positions. The Raun characterisation work and the Johansen pharmacokinetic study (PMID 9849822, PMID 9879640) established the compound’s structural stability framework that translates into in-vial post-reconstitution stability behaviour broadly consistent with the catalog standard.

For a 10 mg vial reconstituted with 2 mL of bacteriostatic water at the typical 100-200 mcg per-day dose tier, the vial supports 50-100 daily draws — substantially more than the 28-day in-use window accommodates. Most research protocols are vial-limited rather than stability-window-limited, with re-reconstitution from a fresh vial driven by vial exhaustion rather than stability concerns.

The combined CJC-1295 + Ipamorelin Blend format uses the same 28-day in-use stability framework applied to the combined formulation rather than per-component — the lower-stability component (whichever it is) governs the practical in-use window.

Why this matters in research context

Ipamorelin’s high stability and low typical per-draw dose mean most research protocols are vial-limited rather than stability-window-limited. The aliquot-and-freeze strategy is less commonly needed than for the larger-dose compounds because typical multi-week protocols complete within the 28-day refrigerated window even at conservative draw cadence. For multi-month protocols, aliquoting at reconstitution remains the standard extended-stability approach.

Related compounds

Related research questions

References

  1. Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998;139(5):552-561. [PMID 9849822]
  2. Johansen PB et al. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica 1998;28(11):1083-1095. [PMID 9879640]
  3. Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm 2000;203(1-2):1-60. [PMID 10967427]

Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Ipamorelin is sold strictly as a research-grade reagent for laboratory and bench research applications.

Shopping Cart
Scroll to Top